Status:
COMPLETED
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Lead Sponsor:
Changhai Hospital
Conditions:
ERCP
Pancreatic Diseases
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.
Detailed Description
ERCP is an important endoscopic technique in the diagnosis and treatment of pancreatic and biliary diseases. Duodenal peristalsis can make cannulation of the papilla and the necessary therapeutic proc...
Eligibility Criteria
Inclusion
- All patients undergoing ERCP above the age of 18 years
Exclusion
- Patient with Billroth II gastrectomy
- Known previous sphincterotomy
- Active acute pancreatitis before ERCP
- Ongoing acute cholangitis before ERCP
- Hypotension (systolic blood pressure \< 100 mmHg)
- Second-degree and third-degree atrioventricular block
- Heart failure
- Glaucoma
- Obstructive uropathy
- Impaired renal function (serum creatinine \> 133μmol/L)
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00731198
Start Date
August 1 2008
End Date
July 1 2009
Last Update
September 8 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fujian Provincial Hospital
Fuzhou, China
2
The First People's Hospital of Hangzhou
Hangzhou, China
3
Heilongjiang Provincial Hospital
Harbin, China
4
Changhai Hospital, Second Military Medical University
Shanghai, China